Summary & Overview

Malignant Breast Disorders with CC: Inpatient Reimbursement Overview

DRG 598 encompasses inpatient stays for malignant breast disorders with a Complication or Comorbidity, covering cases where malignant breast disease is accompanied by an additional condition that increases clinical complexity. This grouping matters for inpatient reimbursement because the Complication or Comorbidity status changes the Diagnosis-Related Group assignment and thus affects Centers for Medicare & Medicaid Services payment weights and hospital case-mix considerations.

Malignant Breast Disorders with CCDRG Malignant Breast Disorders with CCDRG 598Diagnosis-Related GroupInpatient ReimbursementMedicareSurgical OncologyBreast SurgeryOncologyHospital Case Mix

DRG 598 Overview

DRG 598 covers hospital admissions for malignant breast disorders when a Complication or Comorbidity is present; cases typically include patients with invasive breast cancer or other malignant breast neoplasms who have an additional comorbid condition that affects care complexity. This Diagnosis-Related Group groups clinical resource use around surgical, oncologic, and postoperative management of breast malignancy with added clinical complexity. It matters for Medicare payment because the presence of a Complication or Comorbidity adjusts relative payment weights and influences inpatient reimbursement under Centers for Medicare & Medicaid Services rules. Payers and hospitals use this grouping to classify case mix and allocate inpatient resource payments.

Clinical Trials

Neoadjuvant and perioperative systemic therapy trials assessing tumor response and surgical outcomes: These studies enroll patients with operable or locally advanced malignant breast tumors who require inpatient care for complications or comorbidities (the CC in this DRG), testing different chemotherapy, endocrine, or targeted therapy sequences given before surgery to downstage tumors and increase breast-conserving surgery rates. Research focuses on pathologic complete response, rates of conversion to less extensive surgery, and perioperative complication profiles, which matter to providers for operative planning and to payers because treatment sequencing can affect length of stay, readmissions, and downstream surgical resource use.
Comparative effectiveness studies of surgical approaches and inpatient management for complex cases: Trials compare outcomes of mastectomy versus breast-conserving surgery with oncoplastic techniques or immediate reconstruction in patients with malignant breast disease complicated by significant comorbid conditions (the CC population), or evaluate different perioperative care pathways (eg enhanced recovery protocols, inpatient wound care strategies). These studies target patients at higher perioperative risk to determine which approaches reduce complications, ICU utilization, and hospitalization duration, providing evidence to guide coding, reimbursement decisions, and resource allocation for providers and payers.
Post-discharge survivorship and complication-prevention trials focused on high-risk inpatients: These studies follow patients who required inpatient management for malignant breast disease with complicating conditions to test interventions such as structured multidisciplinary follow-up, early home nursing, or targeted infection-prevention bundles to reduce surgical-site infections, lymphedema progression, and 30–90 day readmissions. The patient population includes older adults and those with comorbid illness who are more likely to generate additional inpatient and outpatient costs; results inform discharge planning, case management, and payer investments in transitional-care programs to lower total cost of care and improve long-term outcomes.

Related Codes

594-SKIN-ULCERS-WITHOUT-CC-MCC

Skin Ulcers without CC/MCC: Inpatient Reimbursement Overview

573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

597-MALIGNANT-BREAST-DISORDERS-WITH-MCC

Malignant Breast Disorders with MCC: Inpatient Reimbursement Overview

578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

596-MAJOR-SKIN-DISORDERS-WITHOUT-MCC

Major Skin Disorders without MCC: Inpatient Reimbursement Overview

575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

603-CELLULITIS-WITHOUT-MCC

Cellulitis without MCC: Inpatient Reimbursement Overview

574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

600-NON-MALIGNANT-BREAST-DISORDERS-WITH-CC-MCC

Non-Malignant Breast Disorders with CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 31

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.